Skip to main content

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Coordinator

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Net EU contribution
€ 1 297 406,00
Address
3 Avenue Victoria
75000 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,25

Participants (14)

LEIBNIZ-INSTITUT FUR VIROLOGIE
Germany
Net EU contribution
€ 81 250,00
Address
Martinistrasse 52
20251 Hamburg

See on map

Region
Hamburg Hamburg Hamburg
Activity type
Research Organisations
Non-EU contribution
€ 0,00
EXCELLGENE SA
Switzerland
Net EU contribution
€ 0,00
Address
Route De L'ile-au-bois 1A
1870 Monthey

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Schweiz/Suisse/Svizzera Région lémanique Valais / Wallis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 3 949 573,75
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
Net EU contribution
€ 1 040 108,00
Address
Rue Leblanc 25
75015 Paris 15

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,75
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
Net EU contribution
€ 0,00
Address
Rue Du Bugnon 21
1011 Lausanne

See on map

Region
Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Non-EU contribution
€ 1 437 500,00
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
Net EU contribution
€ 454 195,00
Address
Rue Michel Ange 3
75794 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 79 137,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,50
OLIGOVAX
France
Net EU contribution
€ 863 000,00
Address
102 Avenue Des Champs-elysees
75008 Paris

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Germany
Net EU contribution
€ 182 500,00
Address
Bernhard Nocht Strasse 74
20359 Hamburg

See on map

Region
Hamburg Hamburg Hamburg
Activity type
Research Organisations
Non-EU contribution
€ 0,00
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
Net EU contribution
€ 603 125,00
Address
Avenue Oscar Lambret 2
59037 Lille

See on map

Region
Hauts-de-France Nord-Pas de Calais Nord
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 86 160,50
VAXEAL RESEARCH
France
Net EU contribution
€ 0,00
Address
4 Rue Pierre Fontaine, Pepinere Genopole Enterpris
91058 Evry

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Essonne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 6 068 591,00
UNIVERSITE D'ABOMEY-CALAVI
Benin
Net EU contribution
€ 566 312,00
Address
Campus Universitaires D Abomey
01 Abomey Calavi

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,50
IFAKARA HEALTH INSTITUTE TRUST
Tanzania
Net EU contribution
€ 502 000,00
Address
Kiko Avenue Off Old Bagamoyo Road Plot 463
Dar Es Salaam

See on map

Activity type
Research Organisations
Non-EU contribution
€ 0,00
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO
Italy
Net EU contribution
€ 273 650,00
Address
Via Portuense, 292
00149 Roma

See on map

Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Non-EU contribution
€ 0,00
ISTITUTO SUPERIORE DI SANITA
Italy
Net EU contribution
€ 246 887,00
Address
Viale Regina Elena 299
00161 Roma

See on map

Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Non-EU contribution
€ 0,50